Quantcast
Home > Quotes > CNAT
CNAT

Conatus Pharmaceuticals Inc. Common Stock (CNAT) Quote & Summary Data

$1.38
*  
0.14
9.21%
Get CNAT Alerts
*Delayed - data as of Dec. 17, 2018 14:07 ET  -  Find a broker to begin trading CNAT now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    CNAT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 1.37 / $ 1.38
Today's High / Low
$ 1.59 / $ 1.36
Share Volume
713,615
50 Day Avg. Daily Volume
824,711
Previous Close
$ 1.52
52 Week High / Low
$ 7.949 / $ 1.49
Market Cap
45,738,811
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
713,615
50 Day Avg. Daily Volume:
824,711

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.62

Trading Range

The current last sale of $1.38 is -7.38% Lower than the 52 week low.

Intraday Last 52 Weeks
High: $ 1.59 $ 7.949
 Low: $ 1.36 $ 1.49

Company Description (as filed with the SEC)

We are a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. We are developing emricasan, a first-in-class, orally active pan-caspase protease inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. We believe that by reducing the activity of these enzymes, caspase inhibitors have the potential to interrupt the progression of a variety of diseases. In collaboration with Novartis Pharma AG, or Novartis, we plan to focus on advancing toward registration of emricasan for patients with fibrosis or cirrhosis due to nonalcoholic steatohepatitis, or NASH. Preclinical studies and clinical trials have yielded compelling results that suggest emricasan may have clinical utility in slowing the progression of liver disease regardless of the original cause of the disease.  ... More ...  


Risk Grade

Where does CNAT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 1.50
Open Date:
Dec. 17, 2018
Close Price:
$ 1.52
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info